Bio-Rad Laboratories, Inc. Class A Common Stock vs 10X Genomics Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while 10X Genomics Inc trades at $59 (market cap $7.61B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap. Which is the better fit depends on your goals.
| BIO | TXG | |
|---|---|---|
Market Cap | $9.43B | $7.61B |
Sector | Health | Health |
52-Week High | $356.25 | $58.57 |
52-Week Low | $241.71 | $11.34 |
Enterprise Value | $9.18B | $7.14B |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →